US0042251084
US0042251084
ACADIA Pharmaceuticals Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 3.39B EUR | 4.35B EUR | 3.81B EUR | 4.55B EUR |
Enterprise Value | 2.49B EUR | 4.04B EUR | 3.58B EUR | 4.42B EUR |
Valuation Multiples | ||||
Trailing P/E | 8.87x | 11.45x | 10.14x | 12.23x |
Forward P/E | 22.26x | -- | -- | -- |
Price to Sales | 2.97x | 3.82x | 3.48x | 5.5x |
Price to Book | 2.61x | 3.33x | 3.05x | 3.71x |
EV/Revenue | 2.19x | 3.55x | 3.27x | 5.35x |
EV/EBITDA | 25.32x | 41.1x | 38.58x | 46.89x |
Price to FCF (P/FCF) | 49.34x | 29.91x | 17.93x | 24.77x |
EV/FCF | 36.29x | 27.77x | 16.84x | 24.08x |
FCF Yield | 2.03% | 3.34% | 5.58% | 4.04% |